Tumor necrosis factor, Interleukin-6, and Vascular endothelial growth factor (TNF/IL-6/VEGF)

This entry represents a collective group of three distinct but often interrelated signaling proteins: Tumor Necrosis Factor (TNF), Interleukin-6 (IL-6), and Vascular Endothelial Growth Factor (VEGF). TNF and IL-6 are hallmark pro-inflammatory cytokines that drive the systemic inflammatory response and are central to the pathogenesis of autoimmune diseases like rheumatoid arthritis and Crohn's disease [1][2]. VEGF is a potent angiogenic factor that stimulates the growth of new blood vessels, a process critical for tumor progression and exudative eye disorders such as wet age-related macular degeneration [3]. In many pathological states, these factors act in concert; for example, TNF and IL-6 can stimulate the production of VEGF, creating a link between chronic inflammation and pathological angiogenesis [4]. Therapeutic targeting of these molecules using monoclonal antibodies has transformed the treatment landscape for chronic inflammatory conditions and various cancers, though it requires careful monitoring for immunosuppression and vascular side effects [5].

Other names

TNF-alphaIL6VEGF-APro-inflammatory and angiogenic cytokine groupCachectinB-cell stimulatory factor 2Vascular permeability factor

These targets are modulated via monoclonal antibodies or fusion proteins that bind directly to the circulating ligands (TNF, IL-6, or VEGF) or their respective receptors (TNFR, IL-6R, or VEGFR), thereby neutralizing their biological activity and inhibiting downstream signaling cascades such as NF-kappaB, JAK/STAT, and MAPK/ERK pathways [1][2][3].